- Home
- TXMD vs BOLD Comparison
TXMD vs BOLD Comparison
Compare TXMD & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXMD | BOLD |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 25.7M |
| IPO Year | 2012 | 2024 |
Fundamental Metrics
Financial Performance| Metric | TXMD | BOLD |
|---|---|---|
| Price | $2.23 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 33.0K | ★ 113.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.61 | ★ 90.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | $427.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $90.64 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.72 | $0.96 |
| 52 Week High | $2.95 | $1.79 |
Technical Indicators
Market Signals| Indicator | TXMD | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 47.53 |
| Support Level | $1.05 | $1.15 |
| Resistance Level | $2.54 | $1.20 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 40.91 | 50.00 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.